GLPwatch
Exenatide vs Tirzepatide
Molecule comparison
Last updated 2026-05-28 15:46 UTCExenatide is a GLP-1 receptor agonist used to treat type 2 diabetes, available as Byetta or Bydureon. Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes, obesity, and obstructive sleep apnea, sold as Mounjaro or Zepbound. Exenatide is injected twice daily or weekly, while tirzepatide is taken as a weekly injection.
AI summary of the sources below.
| Exenatide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GIP and GLP-1 receptor dual agonist |
| Status | Approved | Approved |
| Branded products | byetta, bydureon | mounjaro, zepbound |
Compare full details on the Exenatide and Tirzepatide pages.